WBCPI 100.32 0.0% CBA 165.98 2.3557% BHP 40.14 0.0499% RIO 119.0 -0.5931% CSL 256.28 -0.2646% NAB 41.11 1.6819% WBC 34.65 1.1384% ANZ 31.23 0.7094% MQG 235.53 1.7232% SQ2 136.48 -0.6696% WES 77.58 2.0924% NEM 72.14 -2.5003% GMG 36.16 0.0553% FMG 19.32 1.046% RMD 37.55 -0.7139% ALL 74.67 -0.6652% TLS 3.91 -0.5089% WDS 24.91 1.6735% WTC 123.43 0.1217% TCL 13.14 0.1524%
Last update at 2025-02-12T05:10:00Z
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Fri 07 Feb 25, 06:04 PMBMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
Mon 27 Jan 25, 04:40 PMIs CSL Limited (ASX:CSL) Trading At A 30% Discount?
Fri 10 Jan 25, 10:23 PMGSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Fri 04 Oct 24, 04:31 PMSanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
Fri 04 Oct 24, 12:00 PMEXEL vs. CSLLY: Which Stock Is the Better Value Option?
Wed 02 Oct 24, 03:40 PMBreakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Income before tax | 2663.00M | 2779.60M | 2963.10M | 2572.70M | 2341.10M |
Minority interest | -50.00000M | - | - | - | - |
Net income | 2194.00M | 2254.70M | 2375.00M | 2102.50M | 2102.50M |
Selling general administrative | 1086.00M | 688.00M | 731.70M | 691.80M | 574.80M |
Selling and marketing expenses | 1454.00M | 960.70M | 980.20M | 896.20M | 866.80M |
Gross profit | 6708.00M | 5663.50M | 5798.60M | 5176.10M | 4748.70M |
Reconciled depreciation | 831.00M | 542.50M | 495.30M | 610.96M | 536.03M |
Ebit | 3071.00M | 2922.40M | 3198.18M | 2723.50M | 2517.80M |
Ebitda | 3902.00M | 3464.90M | 3629.20M | 3143.30M | 2893.20M |
Depreciation and amortization | 831.00M | 542.50M | 431.02M | 419.80M | 375.40M |
Non operating income net other | - | - | - | - | - |
Operating income | 4884.05M | 4239.47M | 4174.17M | 3936.21M | 2517.80M |
Other operating expenses | 3989.22M | 2951.84M | 2322.20M | 2037.44M | 6410.00M |
Interest expense | 408.00M | 142.80M | 170.80M | 150.80M | 176.70M |
Tax provision | 419.00M | 524.90M | 588.10M | 470.20M | 422.40M |
Interest income | 406.00M | 17.40M | 3.90M | 143.80M | 162.90M |
Net interest income | -406.00000M | -160.60000M | -166.90000M | -219.72898M | -232.28290M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 419.00M | 524.90M | 588.10M | 470.20M | 422.40M |
Total revenue | 13174.00M | 10493.10M | 10265.30M | 9100.50M | 8509.90M |
Total operating expenses | 4606.00M | 3347.40M | 3208.60M | 2929.70M | 2648.80M |
Cost of revenue | 6466.00M | 4829.60M | 4466.70M | 3924.40M | 3761.20M |
Total other income expense net | 136.00M | 81.60M | 44.70M | 50.30M | -176.70000M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 2244.00M | 2254.70M | 2375.00M | 3063.53M | 2735.92M |
Net income applicable to common shares | 2194.00M | 2254.70M | 2375.00M | 2102.50M | 1918.70M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
Total assets | 56931.95M | 36234.00M | 28346.00M | 18156.90M | 15464.60M |
Intangible assets | 8267.00M | 8367.00M | 1450.80M | 1481.60M | 986.00M |
Earning assets | - | - | - | - | - |
Other current assets | 568.99M | 9.00M | 4.20M | 231.80M | 180.80M |
Total liab | 27882.01M | 18408.00M | 13768.50M | 9775.60M | 8937.20M |
Total stockholder equity | 25998.35M | 15786.00M | 14577.50M | 8381.30M | 6527.40M |
Deferred long term liab | - |